CODEX DNA INC (DNAY) Stock Price, Forecast & Analysis
USA - NASDAQ:DNAY - US1920031010 - Common Stock
DNAY Key Statistics, Chart & Performance
The current stock price of DNAY is 1.3 USD. In the past month the price decreased by -5.8%. In the past year, price decreased by -86.13%.
DNAY Latest News, Press Relases and Analysis
DNAY Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.32 | 214.17B | ||
| DHR | DANAHER CORP | 28.59 | 157.85B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 165 | 50.07B | ||
| A | AGILENT TECHNOLOGIES INC | 26.52 | 40.97B | ||
| IQV | IQVIA HOLDINGS INC | 18.58 | 36.74B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.2 | 28.61B | ||
| WAT | WATERS CORP | 29.76 | 22.50B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 37.12 | 18.87B | ||
| ILMN | ILLUMINA INC | 27.54 | 18.46B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.96 | 16.45B | ||
| TEM | TEMPUS AI INC | N/A | 11.53B | ||
| RVTY | REVVITY INC | 19.01 | 10.57B |
Related stock screener links
About DNAY
Company Profile
Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.
Company Info
CODEX DNA INC
9535 Waples Street, Suite 100
San Diego CALIFORNIA US
CEO: Todd R. Nelson
Employees: 212
Phone: 18582284115.0
CODEX DNA INC / DNAY FAQ
What does CODEX DNA INC do?
Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. The company is headquartered in San Diego, California and currently employs 212 full-time employees. The company went IPO on 2021-06-18. Its synthetic biology solution addresses bottlenecks across the multi-step process of building DNA and mRNA, as well as the limitations of existing solutions that prevent the building of DNA and mRNA at a useable scale. Its BioXp system is an end-to-end automated workstation. The firm's products include BioXp systems, including BioXp 3250 system, BioXp kits for generating a range of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. The company has launched eight BioXp kits, three benchtop reagent kits, and various other synthetic biology products, including 14 SARS-CoV-2 full-length genomes and RNA controls, as well as its Vmax X2 cells. The company has placed approximately 200 BioXp systems globally.
Can you provide the latest stock price for CODEX DNA INC?
The current stock price of DNAY is 1.3 USD. The price increased by 8.33% in the last trading session.
What is the dividend status of CODEX DNA INC?
DNAY does not pay a dividend.
What is the ChartMill technical and fundamental rating of DNAY stock?
DNAY has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in CODEX DNA INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DNAY.
What is CODEX DNA INC worth?
CODEX DNA INC (DNAY) has a market capitalization of 38.38M USD. This makes DNAY a Nano Cap stock.
DNAY Technical Analysis
DNAY Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DNAY. DNAY has a bad profitability rating. Also its financial health evaluation is rather negative.
DNAY Financial Highlights
Over the last trailing twelve months DNAY reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -63.94% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0.37 |
DNAY Forecast & Estimates
9 analysts have analysed DNAY and the average price target is 6.63 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.3.
For the next year, analysts expect an EPS growth of -6.4% and a revenue growth 106.09% for DNAY